Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Operating Margin (2017 - 2025)

Historic Operating Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 7.57%.

  • Akebia Therapeutics' Operating Margin rose 409800.0% to 7.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.88%, marking a year-over-year decrease of 2280900.0%. This contributed to the annual value of 31.51% for FY2024, which is 4310500.0% up from last year.
  • Per Akebia Therapeutics' latest filing, its Operating Margin stood at 7.57% for Q3 2025, which was up 409800.0% from 22.55% recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Operating Margin ranged from a high of 26.97% in Q2 2022 and a low of 149.95% during Q2 2021
  • Over the past 5 years, Akebia Therapeutics' median Operating Margin value was 31.0% (recorded in 2023), while the average stood at 48.28%.
  • Data for Akebia Therapeutics' Operating Margin shows a peak YoY increase of 2747300bps (in 2021) and a maximum YoY decrease of -573300bps (in 2021) over the last 5 years.
  • Over the past 5 years, Akebia Therapeutics' Operating Margin (Quarter) stood at 113.28% in 2021, then surged by 92bps to 8.73% in 2022, then surged by 88bps to 1.07% in 2023, then crashed by -2776bps to 30.77% in 2024, then surged by 125bps to 7.57% in 2025.
  • Its Operating Margin stands at 7.57% for Q3 2025, versus 22.55% for Q2 2025 and 23.57% for Q1 2025.